Shan Wu
Corporate Officer/Principal chez VIRIDIAN THERAPEUTICS, INC.
Postes actifs de Shan Wu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Corporate Officer/Principal | 30/10/2023 | - |
Historique de carrière de Shan Wu
Anciens postes connus de Shan Wu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MAGENTA THERAPEUTICS | Investor Relations Contact | 01/10/2021 | 01/09/2023 |
| Corporate Officer/Principal | 01/10/2021 | 01/09/2023 |
Formation de Shan Wu
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |